Cornerstone Pharmaceuticals
Presence
Rafael Holdings is a company listed under the stock ticker RFL (US).
Executives
View the org chart displaying its 12 main executives
Most searched biographies at Cornerstone Pharmaceuticals
- Sanjeev Luther, President, Chief Executive Officer and Chairman of...
- Aaron Drillick, Director
- Joseph Stern, Director
Create your alert
to follow the executive moves at Cornerstone Pharmaceuticals.
Pharmaceuticals
Rafael Holdings has 1,861 competitors including Pfizer (United States (USA)), Sanofi (France) and Johnson & Johnson (United States (USA)).
Popular M&A news in Pharmaceuticals
- MedMen has filed for bankruptcy protection (posted on April 28 2024).
- AstraZeneca has announced the acquisition of Fusion Pharma (posted on March 23 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (posted on March 19 2024).
Popular contacts in Pharmaceuticals
News
Press releases by Cornerstone Pharmaceuticals
- UPDATE - Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Acute Myeloid Leukemia (AML)
- Cornerstone Pharmaceuticals Initiates Phase 1 Trial of CPI-613® (devimistat) in Combination with Chemoradiation for the Treatment of Advanced Pancreatic Cancer
- Cornerstone Pharmaceuticals to Present Pancreatic Cancer Data on CPI-613® (Devimistat) From Its Open-Label Phase 1 Study at the European Society of Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2022
- Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism – UPDATE
- Cornerstone Pharmaceuticals Strengthens Scientific Advisory Board with the Appointment of Distinguished Scholar Jason Locasale, Ph.D.
- Cornerstone Pharmaceuticals to Present Pancreatic Cancer, Clear Cell Sarcoma and Biliary Tract Cancer Research Featuring CPI-613® (Devimistat) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
- Rafael Pharmaceuticals, Inc. Announces Corporate Name Change to Cornerstone Pharmaceuticals, Inc.
- European Medicines Agency Grants Orphan Drug Designation to Cornerstone Pharmaceuticals’ CPI-613® (Devimistat) for Treatment of Patients with Advanced Unresectable Biliary Tract Cancer
- Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Pancreatic Cancer NYSE:RFL
- Rafael Pharmaceuticals Crosses Enrollment of 100th Patient in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML) NYSE:RFL
- View more press releases Close
Social media about Cornerstone Pharmaceuticals
- Cornerstone Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
- Cornerstone Pharmaceuticals on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Sanjeev Luther 
Call Cornerstone Pharmaceuticals at +1 609...
